AHA Coding Clinic® for HCPCS - 2020 Quarter 2; For Your Information
Discontinued HCPCS Level II codes effective July 1, 2020
New HCPCS Level II Code Long Descriptor Date Discontinued C9041 Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mg July 1, 2020 C9053 Injection, crizanlizumab-tmca, 1 mg July 1, 2020 C9054 Injection, lefamulin (xenleta), 1 mg July 1, 2020 C9056 Injection, givosiran, 0.5 mg July 1, 2020 C9057 Injection, cetirizine hydrochloride, 1 mg July 1, 2020 C9058 Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mg July 1, 2020 C9754 Creation of arteriovenous fistula, percutaneous; direct, any site, including all imaging and radiologic supervision and interpretation, when performed and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty...
Subscribe or sign in to view the full article.
Article Overview
This article presents a July 1, 2020 HCPCS Level II discontinuation update and is aimed at coders, billers, compliance staff, and reimbursement teams who monitor code-set changes. It focuses on identifying which HCPCS Level II codes were affected and provides the associated timing so users can update internal references and crosswalks.
Why This Topic Matters
Discontinued HCPCS Level II changes can affect claim preparation, charge capture, and code-set maintenance. This page helps readers identify the affected entries and the effective date of the change.
What You Will Learn
- Which HCPCS Level II entries are identified in a discontinuation update
- How the article is organized around code maintenance dates
- What type of billing and reference maintenance this update supports
- Which categories of HCPCS Level II services are covered by the notice
Who Should Read This
- Medical coders
- Billing specialists
- Compliance teams
- Revenue cycle staff
- Healthcare administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com